fenfluramine
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dravet Syndrome (DS)
Conditions
Dravet Syndrome (DS), Children Under 2 Years
Trial Timeline
Oct 22, 2024 → Jul 1, 2027
NCT ID
NCT06598449About fenfluramine
fenfluramine is a approved stage product being developed by UCB for Dravet Syndrome (DS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06598449. Target conditions include Dravet Syndrome (DS), Children Under 2 Years.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06598449 | Approved | Recruiting |
| NCT06118255 | Phase 3 | Active |
Competing Products
15 competing products in Dravet Syndrome (DS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 30 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 20 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| fenfluramine | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 82 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 72 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 36 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 47 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |